Jeff Bezos Doesn't Want To Get Old Or Die, So He Is Funding Immortality Research
Amazon founder Jeff Bezos recently extended support to Altos Labs, a company aimed at solving the age-old issue of ageing
Jeff Bezos wants to delay ageing, quite literally. The Amazon founder and space enthusiast recently extended financial support to Altos Labs, which is trying to solve one of the worst human ailments - mortality.
Reported first by MIT Tech Review, Altos Labs has also received funding from a Russian billionaire named Yuri Milner and his wife Julia. Milner is quite famous for investing in big companies like Twitter, Spotify, Facebook and Airbnb.
The Altos journey to immortality kicked off earlier this year in the United States and the United Kingdom where the company was incorporated. Now, the company wants to set up institutes in uncharted territories including Japan.
Also read: Billionaire Feud: Elon Musk Tweeted Jeff Bezos Would 'Sue Death' If He Could
It appears that the company is also trying to induct scientists from major universities by offering them high salaries. Bezos is no stranger to similar endeavours. With a net worth of over $200 billion, Jeff Bezos has invested in a series of companies, even others that are trying to solve the problem of mortality.
According to the New York Post, Jeff Bezos has also invested in a start-up called Unity Biotechnology which is also working to "halt or reverse diseases" of ageing.
Also read: Amazon Loyalists Are Cancelling Prime Subscriptions After Jeff Bezos' Spaceflight
A group of scientists met last year for a two-day conference to discuss technology to reverse ageing. This conference culminated in the creation of Altos Labs after scientists pitched their attempts at rejuvenating animals. The company hopes to revive dying cells, with the goal to stretch the lifespan of a human being.
Do you think it's a noble goal to pursue immortality? We would love to hear in the comments. For more on Bezos and his exploits, and of course the pick of our latest science and tech news you wouldn't want to miss, keep following Indiatimes.com.